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ajor depressive disorder (MDD), one of the
most common psychiatric illnesses in the adult popula-
tion, is a major cause of disability
1 and is associated with
a twofold increase in nonsuicidal mortality in women.
2
In addition to poor medical compliance and lifestyle fac-
tors, endocrine, immune, and autonomic dysregulations
may play a causative role in producing medical illnesses
in patients with MDD.
3,4
The goal of this article is to describe some of the most
clinically relevant medical consequences of major
depression by summarizing here the findings of the
POWER (Premenopausal, Osteoporosis Women,
Alendronate, Depression) Study. The medical conse-
quences of depression, as observed in the POWER
Study, included osteoporosis, endocrine and immune
alterations, subclinical inflammation and alterations in
coagulability, chronic pain, and decreased quality of life.
Some of the novel pathogenetic mechanisms unraveled
will be discussed. This review will conclude by listing
some implications for clinical practice and future
research. 
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Major depressive disorder (MDD) is one of the most com-
mon psychiatric illnesses in the adult population. It is
often associated with an increased risk of cardiovascular
disease. Osteoporosis is also a major public health threat.
Multiple studies have reported an association between
depression and low bone mineral density, but a causal
link between these two conditions is disputed. Here the
most important findings of the POWER (Premenopausal,
Osteoporosis Women, Alendronate, Depression) Study,
a large prospective study of bone turnover in pre-
menopausal women with major depression, are sum-
marized. The endocrine and immune alterations sec-
ondary to depression that might affect bone mass, and
the possible role of poor lifestyle in the etiology of
osteoporosis in subjects with depression, are also
reviewed, as is the potential effect of antidepressants on
bone loss. It is proposed that depression induces bone
loss and osteoporotic fractures, primarily via specific
immune and endocrine mechanisms, with poor lifestyle
habits as potential contributory factors.   
© 2011, LLS SAS Dialogues Clin Neurosci. 2011;13:73-87.
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in premenopausal mildly depressed 
women mostly in remission
The POWER study
Women with MDD were characterized with a matched
group of healthy women from an immune, endocrine,
and inflammatory point of view and prospectively fol-
lowed for 36 months, with evaluations at baseline, 6, 12,
24, and 36 months.
5 In the POWER Study, the presence
of a control group prevented artifacts secondary to a
nonspecific “study effect” on mood and provided a
benchmark for the research measurements taken. 
Study design
The POWER Study was a three-year prospective investi-
gation of bone turnover and other measurements con-
ducted at the NIH Clinical Center.
5 Recruitment was con-
ducted from July 2001 to February 2003 in the Washington,
DC, metropolitan area by advertising in newspapers, radio,
flyers and on the Internet. We enrolled 89 community-
dwelling 21- to 45-year-old premenopausal women with
current or recent MDD and 44 healthy control women.
Women were enrolled if they met DSM-IV criteria for
MDD, and had experienced a depressive episode in the
preceding three years. Exclusion criteria were: depression
with suicidal risk, schizophrenia, schizoaffective disorders,
eating disorders, bipolar illness, hyperthyroidism, vitamin
D deficiency, or other conditions or treatments that might
affect bone turnover, and menopause, defined as the
absence of spontaneous menses during the preceding 6
months. Patients treated for depression were allowed to
continue their usual treatment. Patients with anxiety dis-
orders or a history of alcohol or drug dependence in remis-
sion for 5 years were eligible. Controls were also excluded
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Selected abbreviations and acronyms
BMD Bone mineral density
CRP C-reactive protein
HPA hypothalamic-pituitary-adrenal
MDD major depressive disorder
PAI-1 plasminogen activator inhibitor
Figure 1. Study flow diagram. The number of subjects screened, reasons for exclusion, and number of subjects enrolled in the study are listed.
Reproduced from ref 5: Eskandari F, Martinez PE, Torvik S, et al. Premenopausal, Osteoporosis Women, Alendronate, Depression (POWER) Study Group.
Low bone mass in premenopausal women with depression. Arch Intern Med. 2007;167:2329-2336. Copyright © American Medical Association 2007
MDD group:
120 women screened
Excluded: 31 women
bipolar disorder, depression
secondary to  PTSD, eating disorder,
substance abuse
Enrolled:
89 woment with MDD
10 No MDD episode in last 3 years •
7 As per exclusion criteria: •
5 Depressive disorder, NOS •
5 Incomplete screening •
2 Medication use: lithium, steroids •
1 Postmenopausal •
1 Vitamin D deficiency •
Control group:
63 women screened
Excluded: 19 women
anxiety disorder, substance abuse,
eating disorder
Enrolled:
44 healthy controls
7 History of MDD •
4 As per exclusion criteria: •
2 Vitamin D deficiency •
1 Hyperthyroidism •
1 Hyperparathyroidism •
1 Severe back pain •
1 History of melanoma •
1 Medication use: dexatrim •
1 Withdrew consent •
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past alcohol abuse. Control women were individually
matched with a subset of 44 patients with MDD based on
age (+3 years) and body mass index (BMI) (+2.0). Except
for two pairs, all other pairs were also matched by self-
defined race. The Institutional Review Board of the
National Institute of Mental Health approved this study.
Written informed consent was obtained from each partic-
ipant. The trial was registered in ClinicalTrials.gov, NCT
00006180. Figure 1 depicts the number of individuals
screened and the reasons for exclusion.
Study sample
The study sample was composed of mostly Caucasian,
college-educated women in their mid-30s. Smoking,
intake of calcium, caffeine and alcohol, and physical fit-
ness were similar between groups. 
Clinical features of the participants
Seventeen percent of women with MDD were currently
depressed (defined as a depressive episode during the
preceding 4 weeks). On average, women with MDD
exhibited mild symptoms of depression and anxiety and
had a good level of functioning. However, the cumula-
tive history of depression averaged approximately 5
years and four episodes of depression. Age of onset of
depression was in the late teens, and approximately one
half of the patients with MDD also suffered or had pre-
viously suffered from anxiety disorders. More than 80%
of the women with MDD were taking antidepressants. 
Low bone mass 
Bone mineral density (BMD) was approximately 2%
lower in MDD subjects versus controls at the AP spine
and at the femoral neck, and tended to be lower at the
radius; T-score (a comparison of a patient’s BMD to that
of a healthy 30-year-old of the same sex and ethnicity)
was significantly lower at the femoral neck and the
radius. The prevalence of low BMD was greater in
women with MDD vs controls (28% vs 11%, P=0.04);
greater at femoral neck (17% vs 2%, P=0.02) and total
hip (15% vs 2% P=0.03), and tended to be greater at the
lumbar spine (20% vs 9%; P=0.14). 
Twenty-five women with MDD had a T-score lower than
-1 SD at the spine or hip, and two of these women had
osteoporosis, defined as a T-score at the AP spine or hip
lower than -2.5 SD. These 25 women had significantly
lower BMI and weight (P<0.001), and were less physi-
cally fit (P<0.001) than did women with MDD and nor-
mal BMD and higher T-scores. Of 73 women with MDD
who were taking an antidepressant medication at the
time of enrollment, 54 were taking one form of selective
serotonin reuptake inhibitors. 
Main findings
One in five premenopausal women with MDD exhibited
low BMD. Decreased bone mass was especially common
at the hip: hip fractures are the most serious consequence
of osteoporosis. The bone mass deficits observed were of
clinical significance. The 2% difference observed at the
hip is similar to or greater in magnitude than that of rec-
ognized osteoporosis risk factors such as cigarette smok-
ing, lack of exercise, and absence of calcium supplemen-
tation.
6-8 Because the relationship between BMD and
fracture risk is exponential, small deficits in BMD trans-
late into larger increases in fracture rates. Given a preva-
lence of MDD in the 134 million US women between the
ages of 21 and 45 of approximately 16%,
9 we estimate
that nearly 4 million women with MDD may have unde-
tected deficits in BMD of similar magnitude.
How do the bone findings relate to the rest of the 
literature? Depression and osteoporosis: a research 
synthesis with meta-analysis
In spite of the evidence reported here and many other
published reports since 1994,
10 neither depressive symp-
toms nor MDD currently appear among the risk factors
for osteoporosis in official statements. In the last NIH
consensus conference on osteoporosis, depression was
not listed as a risk factor for osteoporosis. Furthermore,
a 2006 issue of Endocrine News, an official publication
of the US Endocrine Society, contained an exhaustive
table listing 19 causes of secondary osteoporosis, includ-
ing bone loss secondary to space flight in astronauts, but
failed to mention depression for secondary osteoporo-
sis!
11 The sustained need to change this incorrect, long-
standing perception prompted us to perform a meta-
analysis of the 20 original articles on bone mass in
subjects with depression.
12 At each site, bone mass was
lower in subjects with depression as compared with con-
trols: AP spine bone mineral density was 4.73% lower,
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Figure 2. Meta-analysis forest plots for AP spine bone mineral density (BMD), total femur BMD and femoral neck BMD. (A) AP spine BMD: Most studies
show lower AP spine BMD in depressed subjects, with 3 studies indicating that BMD was higher in controls. (B) Total femur: Most studies show
lower total femur BMD in depressed subjects, with 3 studies indicating that BMD was higher in controls, and 2 studies showing no difference. (C)
Femoral neck BMD: Most studies show lower femoral neck BMD in depressed subjects, with three studies indicating that BMD was higher in con-
trols. For each one of these three graphs under the first column are listed in chronological order the studies included and the year of publication;
these studies are subdivided in studies conducted only in women, only in men, and studies conducted in men and women. Studies that utilized
DSM criteria to characterize depression are indicated with a dagger. In the last column the relative weight of each individual study is reported.
Reproduced from ref 12: Cizza G, Primma S, Coyle M, Gourgiotis L, Csako G. Depression and osteoporosis: a research synthesis with meta-analysis. Horm
Metab Res. 2010;42 :467-482. Copyright ©Thieme 2010
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femoral neck bone mineral density was 7.32% lower
(Figure 2). The deficits in bone mineral density in sub-
jects with depression are of clinical significance and
likely to increase fracture risk over the lifetime of these
subjects. 
Increased abdominal fat and increased serum levels of
prothrombotic factor
Both central adiposity
13,14 and increased plasminogen
activator inhibitor (PAI) -1 concentration
15,16 are associ-
ated with increased risk of cardiovascular diseases. PAI-
1 is an important pathophysiological link between vis-
ceral obesity, insulin resistance, and cardiovascular
diseases.
17,18 Subjects with MDD are prone to increased
central fat distribution.
19,20 Although the exact mecha-
nisms are not known, alterations of the hypothalamic-
pituitary-adrenal (HPA) axis secondary to depression,
such as increased 24-hour plasma cortisol concentra-
tion,
21,22 could contribute to central obesity.
23,24
Augmented coagulability due to increased concentration
or activity of coagulation factors
25,26 and PAI-1
27,28 has in
fact been reported in other hypercortisolemic states,
such as Cushing’s syndrome, and in patients treated with
glucocorticoids.
We tested whether MDD was associated with changes
in the prothrombotic factors, PAI-1 and fVIII, as well as
with altered body fat distribution, which may lead to
hypercoagulability, and subsequent cardiovascular dis-
eases.
29We also assessed whether these factors correlate
with the severity of depression and cortisol concentra-
tion. 
PAI-1 concentration (Figure 3) and fVIII activity were
significantly higher at 0800 h than 2000 h in both the
MDD and control groups, confirming the existence of
circadian rhythmicity. Both PAI-1 and fVIII were sig-
nificantly higher at 2000 h in women with MDD than in
controls.
Women with MDD had higher PAI-1 concentration and
fVIII activity and more abdominal fat than healthy con-
trols. Increased central body fat in association with
symptoms of depression and anxiety has already been
reported in large epidemiological studies of men and
women.
19,20 The increase in prothrombotic factors in
young women with MDD, reported for the first time in
the POWER Study, is likely to be of clinical importance.
These abnormalities persisted after correction for body
weight, and were even more evident in the subset of sub-
jects individually matched for age and BMI, suggesting
that the association between depression and these fac-
tors was specific.
PAI-1 concentrations were similar to those reported in
the subjects who later developed diabetes mellitus in a
large prospective study.
30 Similarly, increased risk of dia-
betes mellitus has been reported in subjects with
increased fVIII activity.
31
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Figure 3. Plasminogen activator-1 (PAI1). PAI-1 concentrations exhibit an
exponential distribution both in subjects with MDD and controls.
Panel A: 0800 h PAI-1 concentration. Panel B: 2000 h PAI-1 con-
centration.
Reproduced from ref 29: Eskandari F, Mistry S, Martinez PE, et al;
POWER (Premenopausal, Osteopenia/Osteoporosis, Women,
Alendronate, Depression) Study Group. Younger, premenopausal
women with major depressive disorder have more abdominal fat and
increased serum levels of prothrombotic factors: implications for greater
cardiovascular risk. Metabolism. 2005;54:918-924. Copyright © W. B.
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C-reactive protein (CRP), a nonspecific marker of
inflammation, is regarded as a risk factor for cardiovas-
cular events. Recently, it has been proposed to include
CRP as a clinical criterion for the metabolic syndrome
as well.
32 CRP is being proposed as a marker clinically
useful for following prospectively subjects; however, only
limited information on its variability over time exists.
The reported variability over a week is approximately
30% to 50%, underlining the importance of performing
serial sampling, especially if the values are in a high
range.
33 Of note, a diurnal variation in CRP levels with a
peak at 15:00, as well as a small seasonal variation with
highest values at winter-time were recently noted in a
45-year old population of a large cohort study of healthy
men and women.
34
Women with MDD tended to have consistently higher
CRP levels than controls over 12 months (P=0.07).
35
BMI was positively related to log [CRP] in women with
MDD only. Nine women out of 77 women with MDD
had CRP levels greater than 10 mg/L, a value associated
with a very high cardiovascular risk (Figure 4). This sub-
set was obese and had significantly higher triglycerides,
total cholesterol, LDL-cholesterol, fasting insulin, and
Homeostasis Model Assessment–Insulin Resistance
(HOMA-IR) than the rest of women with MDD. The
variations in CRP levels over time were high (intra- and
interindividual coefficients of variations of ~30-50% and
~70-140%, respectively). No control had CRP levels
greater than 10 mg/L.
Approximately 16% of the 134 million US women
between the ages of 21 and 45 are or have been suffer-
ing from MDD. Hence, millions of women currently may
have abnormal CRP levels, especially when associated
with obesity. 
Elevated neuroimmune biomarkers in plasma and
sweat
Elevated cytokine levels have been reported in plasma
of subjects with MDD, with inconsistent results.
36,37 HPA
axis abnormalities, alterations in autonomic and pain
mediators, including vasoactive intestinal peptide (VIP),
neuropeptide Y (NPY), substance P (SP), and calcitonin-
gene-related peptide (CGRP), have also been reported
with inconsistent results and could contribute to immune
dysregulation.
38,39 Elevated cytokines in MDD have been
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Figure 4. Analysis of baseline C-reactive protein (CRP) levels in women with
major depressive disorder (MDD) and healthy control women.
Upper panel: Box plots showing median, quartiles, and extreme
values. The box represents the values between the 25th and 75th
percentiles. The horizontal bar across each box represents the
median value. Asterisks represent extreme values (values more
than 3 box lengths from the upper edge of box). Open circles rep-
resent outliers (values between 1.5 and 3 box lengths from upper
edge of box). One depressed subject with high CRP levels (29.3
mg/L) had reported recovery from an acute infection at the time
of visit and was therefore excluded from the analyses. Lower
panel: Percentile distribution of CRP values. CRP values for select
percentiles are shown in the inset table. At the uppermost per-
centile (75th), women with MDD have CRP levels over twice as
high as control women. The dashed line marks the CRP level of
10 mg/L above which there are only MDD subjects.
Reproduced from ref 35: Cizza G, Eskandari F, Coyle M, et al; P.O.W.E.R.
(Premenopausal, Osteoporosis Women, Alendronate, Depression) Study
Group. Plasma CRP levels in premenopausal women with major depres-
sion: a 12-month controlled study. Horm Metab Res. 2009;41:641-648.
Copyright © Thieme 2009
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PAGES_11_AG_1040_BA.qxd:DCNS#48  5/03/11  11:36  Page 79linked to osteoporosis, diabetes, cardiovascular disease,
sleep disturbances, and decreased pain threshold.
At first, we measured cytokine concentration in plasma
hourly for 25 hours, using recycling immunoaffinity chro-
matography (RIC) coupled with laser-induced fluores-
cence detection, a highly sensitive and specific method-
ology, to measure multiple analytes in minute volumes.
5
Compared with the 14 controlled women, the 17 women
with MDD had much higher concentrations of the
proinflammatory cytokines interleukin (IL)-1β, IL-2, IL-
6 and tumor necrosis factor (TNF)-α, similar levels of
the anti-inflammatory cytokine IL-10, and lower levels
of anti-inflammatory IL-13. Twenty-four-hour blood
drawing allows for a more comprehensive assessment of
cytokine levels than single-time measurements. As many
of these cytokines were secreted in a circadian fashion,
performing measurements around the clock provides a
window on biorhythms and their potential disruption as
a consequence of depression. This method is however
invasive and impractical, as it can only be performed in
an inpatient setting. 
Skin patch, a novel method for collection of cytokines
in sweat
We therefore developed and validated a skin patch, a
novel method to measure cytokines in the sweat. The
skin patch coupled with RIC, previously validated in
healthy controls
40 allowed identification of a specific pat-
tern of neuroimmune dysregulation not previously
detected in mildly depressed women. Women with MDD
exhibited in sweat several fold elevations of proinflam-
matory cytokines, sympathetic (NPY) and sensory (SP
and CGRP) neuropeptides, and diminished parasympa-
thetic-associated neuropeptide, VIP.
41 Cytokine levels in
sweat closely related to the levels in plasma. This
methodology avoids confounds to biomarker measure-
ments associated with previous methods of sweat col-
lection (exercise,
42 sauna heat,
43 and blood drawing.
37An
elevation in proinflammatory cytokines of this magni-
tude substantially increases medical morbidity including
osteoporosis, cardiovascular disease, and metabolic dis-
orders. Cytokines also regulate neurotransmitters, hor-
mones, and neuropeptides
44 and modulate many behav-
iors, including mood, pain, and sickness behavior which
are dysregulated in patients with depression. 
The elevated sympathetic (NPY) and sensory (SP and
CGRP)-associated neuropeptides in both sweat patch
eluates and plasma are consistent with their role in
depression, This pattern of higher levels of proinflam-
matory cytokines, lower VIP (parasympathetic activity),
and higher NPY (sympathetic activity) in patients with
MDD, could be associated with increased cardiovascu-
lar risk in patients with MDD. 
The elevated levels of SP and CGRP reported here con-
firm previous reports of the role of these peptides in
pain perception, and of painful somatic symptoms cor-
relating with depression severity in up to two thirds of
patients with MDD.
39The lower VIP levels we observed
are consistent with reduced parasympathetic tone that
has been reported in depression, and with the effective-
ness of parasympathetic vagal stimulation in treatment
of refractory depression.
45
Novel endocrine alterations in women with MDD: 
low 24-hour adiponectin and high nocturnal leptin 
concentration
MDD is associated with endocrine and immune system
dysfunction and quite indirectly disruption of multiple
circadian systems. White adipose tissue, an organ with
endocrine functions, secretes the adipocytokines, leptin
and adiponectin. Leptin signals to the central nervous
system (CNS) the amount of energy stores to regulate
food intake and energy expenditure.
46 If adequate body
fat is present, energy can be expended for costly
processes like reproduction and growth. Leptin modu-
lates several endocrine axes, including the HPA axis by
negative feedback at the hypothalamus, and elevated
leptin has been associated with osteopenia (reviewed in
ref 47). Leptin controls appetite, food intake, sexual mat-
uration, and reproductive functions, and immune func-
tions, all of which are disrupted in depression. This hor-
mone is secreted in an exquisitely pulsatile fashion; its
secretion is inversely related to those of ACTH and cor-
tisol. Reports of serum leptin levels in depressed sub-
jects are conflicting, with studies finding either no dif-
ferences, lower levels in depressed men, elevated levels
in depressed men and women, or elevated levels only in
depressed women.
Adiponectin was first reported as an adipocyte secretory
protein in 1995, but only recently has its physiology been
investigated.
48 Plasma adiponectin concentrations are
about two to three times greater than those of most
other hormones, and its concentrations, unlike those of
Clinical research
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Adiponectin receptors (AdipoR1 and R2) have been
identified in the periphery and CNS. AdipoR1 is abun-
dant in skeletal muscle and AdipoR2 exists primarily in
the liver.
46AdipoR1 and AdipoR2 are also present in the
paraventricular nucleus of the hypothalamus, amygdala,
area postrema and, diffusely, in the periventricular areas
and cortex.
While leptin’s rhythmicity is well described,
adiponectin’s 24-hour secretory profile is not well
known. Adiponectin exhibits diurnal and ultradian
rhythms in normal-weight men.
49 Circulating concentra-
tions of adiponectin have been reported in depressed
patients, but only at single time points. In some such
studies, adiponectin was lower in newly diagnosed and
drug-naïve MDD subjects, and was inversely related to
depression severity.
50 However, in others, there was no
significant relationship between single adiponectin mea-
surements and depressive symptoms.
51 To date, 24-hour
secretory profiles of adiponectin have not been
described in MDD patients. Because MDD subjects
have a higher CVD prevalence, and reduced adiponectin
is associated with negative health consequences,
adiponectin rhythmicity in patients with depression is of
interest. The relationship of adiponectin to the HPA axis
and leptin also remains unknown in MDD subjects.
In a satellite study
47 we aimed to establish: (i) whether
women with MDD have decreased circulating concen-
trations of adiponectin and/or disruption of adiponectin
secretory rhythmicity; (ii) the relationship of adiponectin
and leptin secretion with depression; (iii) the temporal
correlations among circadian concentrations of
adiponectin, leptin, ACTH, and cortisol.
From the whole POWER sample, we individually
matched 23 consecutively studied women with MDD
with 23 control subjects, based on age ±3.0 years and
BMI ±2.0 kg/m
2. In control subjects, diurnal fluctuation
in adiponectin was about 30% (Figure 5, upper panel).
Adiponectin was higher during the day, with a zenith
around 1430 h, an initial fall around 1600 h, a further
decline after 2300 h and then another increase at about
0300 h. Women with MDD exhibited similar adiponectin
rhythmicity. Mean adiponectin concentrations were
about 25% lower at all 24-h time points in women in the
MDD versus control group. The diagnosis of MDD
accounted for approximately 25% to 30% of the vari-
ability in adiponectin (0800 h adiponectin R
2 0.285;
P=0.004; 24-h mean adiponectin R
2 0.267; P=0.001).
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Figure 5. Mean 24-hour plasma adiponectin and leptin concentrations in
women with major depressive disorder (MDD, N=23) and Controls
(N=23). Upper panel adiponectin concentrations: In both
groups, adiponectin exhibited a circadian variation characterized by
slightly higher values during early afternoon with a peak around
1400 h. Adiponectin remained lower in women with MDD over 24
h. 0800 h and 24 h mean adiponectin was significantly lower in
women with MDD compared with controls (0800 h Padjusted for
weight =0.0053; mean 24-h Padjusted for weight =0.042; analy-
sis of covariance). Error bars represent SEM. Lower panel leptin
levels. In both groups, leptin exhibited a circadian variation char-
acterized by a nocturnal zenith around 0200 h and a nadir around
1000 h. Leptin remained higher in women with MDD over 24 h.
0800 h and 24 h mean leptin was significantly higher in women
with MDD compared with controls (0800 h P adjusted for weight
=0.010; mean 24-h P adjusted for weight =0.021; analysis of
covariance). Mean nocturnal (2000 h-0400 h) leptin, was greater
in women with MDD than controls (21.05 + 0.91 ng/mL vs 16.10
+ 0.98 ng/mL, respectively, P<0.001). Error bars represent SEM.
Reproduced from ref 47: Cizza G, Nguyen VT, Eskandari F, et al; POWER Study
Group. Low 24-hour adiponectin and high nocturnal leptin concentrations
in a case-control study of community-dwelling premenopausal women with
major depressive disorder: the Premenopausal, Osteopenia/Osteoporosis,
Women, Alendronate, Depression (POWER) study. J Clin Psychiatry.
2010;71:1079-1087. Copyright © Physicians Postgraduate Press 2010
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duration of depression (R=-0.51; P=0.03) and tended to
be inversely related to the duration and severity of
depression (R=-0.41; P=0.09). Adiponectin accounted
for approximately 20% of the waist-hip ratio variability
(0800 h adiponectin R
2 0.194;  P=0.002; 24-h mean
adiponectin R
2 0.230; P=0.007). 
Leptin was higher in women with MDD at all 24-h time
points. Leptin’s rhythmicity was similar between groups.
In control subjects, leptin exhibited its typical diurnal
variation, with higher concentrations during the night,
and a zenith around 0200 h. The lowest concentrations
were observed during the day, with a nadir around 1100
h. Leptin was higher in women with MDD at all 24-h
time points. Leptin’s rhythmicity was similar between
groups. 
Adrenocorticotropic hormone (ACTH) and cortisol
showed typical diurnal variations, with higher values in
the morning. The HPA axis was only marginally altered
in this sample of women with MDD. There were no dif-
ferences in circadian secretion between groups; however,
0800 h ACTH was somewhat higher in women with
MDD than in control subjects (P=0.05). 
In summary, women with MDD exhibited lower circa-
dian adiponectin plasma concentrations than did closely
matched control subjects. As reduced adiponectin has
been shown to predict type 2 diabetes mellitus (T2DM)
and cardiovascular disease (CVD), premenopausal
women with MDD may be at increased risk for both
conditions. Women with MDD also had increased noc-
turnal leptin, elevated morning ACTH, and decreased
nocturnal ACTH and cortisol. ACTH and cortisol were
more strongly related in women with MDD than in con-
trol subjects, suggesting mild HPA-axis activation in
women with MDD.
A 25% decrease in adiponectin has been reported in
prospective studies to increase the risk of T2DM and
CVD.
49-51 In addition, to our knowledge, this was the first
report describing the circadian rhythm of adiponectin in
women with MDD. It is possible that short sleep and/or
sleep disruption decreased adiponectin secretion. Sleep
disturbances are one of the components of the depressive
syndrome, according to DSM-IV criteria, and approxi-
mately 60% of depressed patients have insomnia.
Women with MDD had approximately 25% higher con-
centrations of leptin; because MDD is a state of
increased sympathetic tone,
52 higher leptin may have
been secondary to activation of the sympathetic nervous
system, which is known to stimulate leptin secretion.
Leptin has been shown in a mouse model to centrally
inhibit bone formation via the sympathetic system.
Apposition of new bone takes place mostly at night, as
indicated by circadian measurements of markers of bone
turnover
53; therefore higher nocturnal leptin levels may
contribute to the development of osteoporosis in women
with MDD.
Glucocorticoid receptor gene polymorphisms in
women with MDD: relevance to central obesity
Glucocorticoid receptor (GR) gene polymorphisms are
associated with glucocorticoid hypersensitivity and vis-
ceral obesity. Structural alterations in GR gene are
known to affect target tissue responsiveness to gluco-
corticoids. Two polymorphisms, Bcl1 and N363S, have
been associated with central obesity and altered gluco-
corticoid sensitivity.
54 Furthermore, Bcl1 polymorphism
has been linked to visceral obesity in homozygous (GG)
carriers,
55 higher sensitivity to dexamethasone,
54 higher
salivary cortisol,
56 and hyperinsulinemia.
57An association
between major depressive disorder (MDD) and Bcl1
polymorphism was noted recently.
58,59
We examined the relative distribution of specific poly-
morphisms of GR (Bcl1, N363S, rs33388, rs33389) in
women with MDD compared with healthy controls.
60
Both the rs33888 and rs33889 polymorphisms of the GR
gene were included in the study to explore a potential
role between altered glucocorticoid sensitivity and
MDD.
61 We also explored whether GR polymorphisms
were associated with abdominal obesity and insulin
resistance. For Bcl1 SNP homozygous GG polymor-
phism was significantly more frequent (P=0.03) in
women with MDD than in controls. In the total sample
the genotype frequencies were 41.9% for CC, 43.2% for
CG, and 14.81% for GG genotypes, respectively. GG
homozygotes had slightly higher waist-to-hip ratio
(WHR) than non GG carriers (GG: 0.9±0.07, non GG:
0.8±0.05; P<0.02), although BMI was similar in both
groups. 
Women with MDD were more likely to be carriers of a
specific polymorphism (GG) of Bcl1in the GR gene with
a genotype frequency of 15%. The relationship between
Bcl1 polymorphism and MDD may be explained at least
in part by GR hypersensitivity to glucocorticoids, as
demonstrated by the increased response to ACTH and
cortisol suppression with low-dose dexamethasone in
Clinical research
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had also higher BMI and abdominal adiposity than con-
trols: in particular, women with MDD and Bcl1 GG
genotype of Bcl1 had higher WHR as compared with
their non GG counterparts. This suggests that GG geno-
type confers suceptibilty to increased abdominal fat
independent of total body adiposity. Glucocorticoids
promote intra-abdominal fat accumulation through var-
ious mechanisms. Omental fat has a higher glucocorti-
coid binding capacity than subcutaneous fat, more tran-
scriptional activity of GR and greater sensitivity of
glucocorticoids on lipoprotein lipase activity.
62
In summary, premenopausal women with MDD had
higher BMI, WHR, total body fat, and abdominal fat
percent compared with controls. Homozygous Bcl1 GG
genotype was more frequent in these subjects, as was a
higher WHR without higher BMI. 
Does all the above matter? Chronic pain: the role of
substance P and calcitonin-gene-related peptide
Whereas it is established that organic pain may induce
depression, it is unclear whether pain is more common
in healthy subjects with depression. Patients with MDD
may present with somatic symptoms, including aches and
pain. The prevalence of pain in patients presenting with
MDD, in whom pain was not the primary complaint, has
not been well studied. We established the prevalence of
pain and associated symptoms and determined whether
there is a relationship between pain intensity and the
clinical features of depression.
39 We also administered
two scales of everyday stressors, the Hassles and Uplifts
Scales and a widely used quality-of-life instrument, the
SF-36.
Pain and associated symptoms
Pain was much more common in depressed subjects and,
within subjects with depression, in depressed subjects
with atypical or melancholic episode subtypes. Pain loca-
tion was distinct; the head and neck were the most com-
mon sites. The intensity of pain was mild. Women with
depression reported average values of approximately 2
(range 0-10) in all seven (general activity, mood, walking
ability, normal work, relations with others, sleep, and
enjoyment of life) interferences scales. Therefore, in
women with depression, pain interfered with the activi-
ties inquired, but only to a mild extent. Fatigue, anxiety,
and concentration and memory problems were more
prevalent in subjects with depression. A greater propor-
tion of subjects with depression than controls (57% vs
25%; P=0.01) experienced four or more symptoms com-
monly associated with pain. The vast majority of
depressed subjects reported having at least one symp-
tom, while nearly half of controls were symptom-free.
Relationship between pain intensity and clinical features
of depression
Pain intensity was significantly related with the current
severity of depression (r
2=0.076; P=0.04), and tended to
be related with the current severity of anxiety (r
2=0.065;
P=0.07), and the number of episodes of depression (r
2=
0.072; P=0.09). 
Cytokine and neuropeptide measurements 
Women with depression had higher mean circulating
levels of SP and CGRP than controls (Figure 6). Both
Substance P (SP) and calcitonin-gene-related-peptide
(CGRP), two neuropeptides which are known mediators
of pain, exhibited a 24-h single cosinor rhythm in women
with depression which was remarkably similar to con-
trols; the zenith occurred at 12:24 and 12:15 respectively,
and the nadir at 00:24 and 00:15, respectively. SP (zenith:
13:50, nadir: 01:50) exhibited a significant rhythm in con-
trols whereas no significant rhythm in CGRP was
observed in controls. 
Quality of life 
Women with depression reported a lower quality of life.
They scored lower than controls in the emotional and
social well-being domain of the SF-36, as well as in one
dimension of the physical well-being domain, general
health. Thus, they described themselves as being less
vital, affected emotionally, and impaired in their social
life. The impact of their depression on quality of life was
comparable to that reported in subjects with breast can-
cer or morbid obesity.
63,64
Daily hassles and uplift scale
Daily hassles occurred more frequently and more
severely in women with depression. These included: wor-
ries about physical appearance, misplacing things, and
Clinical consequences of depression - Cizza Dialogues in Clinical Neuroscience - Vol 13 . No. 1 . 2011
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rienced daily uplifts to a similar extent. 
Summary
Women with depression had a higher prevalence of pain
than generally reported in the literature. SP and CGRP,
two pain-related neuropeptides, were higher around the
clock in depressed subjects compared with controls. 
Implications for practice and 
future research
Bone loss
The usefulness of antidepressants for bone loss in MDD
should be evaluated. Prospective studies should estab-
lish whether women with MDD experience a more sus-
tained bone loss during the peri- or postmenopausal
period than nondepressed women. Exploratory studies
of bone mass should be conducted in conditions associ-
ated with an activation of the sympathetic nervous sys-
tem, such as post-traumatic stress disorders. The possi-
bility that subjects with depression may fail to reach
peak bone mass should be investigated. 
Prothrombotic factors
Increased levels of prothrombotic factors may explain
some of the mechanisms leading to augmented risk of
cardiovascular disease in depression. The clinical signif-
icance of our observations should be further validated
in large prospective studies.
CRP
This should be measured in women with depression, espe-
cially if overweight. Since dieting is effective in lowering
CRP levels,
65 weight loss might be recommended even in
moderately overweight women with depression, especially
if they have higher CRP levels and/or other cardiovascu-
lar risk factors. Given its large day-to-day variability, clin-
ical decisions should be based on at least two CRP serial
measurements taken several days apart. CRP is a well-
accepted marker of inflammation; however, it is not clear
whether CRP is itself a risk factor for cardiovascular dis-
ease. Therefore, large-scale use of CRP measurements
should await the proof that it is involved in the patho-
genesis of cardiovascular disease. CRP should be mea-
sured by the high sensitivity assay and because of its
skewed distribution it should be classified based on cut-
points established in prospective clinical trials and clini-
cally interpreted in conjuction with the lipid values. 
Cytokines and sweat patch
Given their circadian variability
66 they should be mea-
sured by frequent sampling in inpatient setting or in the
Clinical research
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Figure 6. Plasma levels of substance P (SP) and calcitonin-gene-related-
peptide (CGRP). Mean 24-h levels of SP (upper panel) and CGRP
(lower panel) were lower in women with depression compared with
controls.
Reproduced from ref 39: Hartman JM, Berger A, Baker K, et al. Quality of life
and pain in premenopausal women with major depressive disorder: The
POWER Study. Health Qual Life Outcomes. 2006;4 :2. Copyright © Biomed
Central 2006
(n=14)
A
v
e
r
a
g
e
 
o
f
 
S
P
 
i
n
d
e
p
r
e
s
s
e
d
 
a
n
d
 
c
o
n
t
r
o
l
0
32
64
80
96
48
16
Control
(n=14)
A
v
e
r
a
g
e
 
o
f
 
C
G
R
P
 
i
n
d
e
p
r
e
s
s
e
d
 
a
n
d
 
c
o
n
t
r
o
l
P  0.0001
P  0.0003
0
16
32
40
48
24
8
Depressed
Control Depressed
8
6
4
2
0
S
P
 
(
p
g
/
m
L
)
Depressed
Controls
Time of day (h)
22 2 4 8 20 18 16 14 12 10 6 0 8
140
120
100
80
60
4
3
2
1
0
C
G
R
P
 
(
p
g
/
m
L
)
70
60
50
40
30
(
n
=
1
7
)
(
n
=
1
7
)
PAGES_11_AG_1040_BA.qxd:DCNS#48  5/03/11  11:36  Page 84Clinical consequences of depression - Cizza Dialogues in Clinical Neuroscience - Vol 13 . No. 1 . 2011
85
REFERENCES
1. Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically
ill: scientific review and recommendations. Biol Psychiatry. 2005;58:175-189.
2. Zheng D, Macera CA, Croft JB, et al. Major depression and all-cause
mortality among white adults in the United States. Ann Epidemiol.
1997;7:213-218.
3. Chrousos GP, Gold PW. The concepts of stress and stress system disor-
ders. Overview of physical and behavioral homeostasis. JAMA.
1992;267:1244-1252.
4. Brown ES, Varghese FP, McEwen BS. Association of depression with
medical illness: does cortisol play a role? Biol Psychiatry. 2004;55:1-9.
5. Eskandari F, Martinez PE, Torvik S, et al. Premenopausal, Osteoporosis
Women, Alendronate, Depression (POWER) Study Group. Low bone mass
in premenopausal women with depression. Arch Intern Med.
2007;167:2329-2336.
6. Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smok-
ing on bone mineral density. Calcif Tissue Int. 2001;68:259-270.
7. Bonaiuti D, Shea B, Iovine R, et al. Exercise for preventing and treat-
ing osteoporosis in postmenopausal women. Cochrane Database Syst Rev.
2002;3:CD000333.
8. Shea B, Wells G, Cranney A, et al. Calcium supplementation on bone
loss in postmenopausal women. Cochrane Database Syst Rev.
2004;1:CD004526.
9. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major
depressive disorder: results from the National Comorbidity Survey
Replication (NCS-R). JAMA. 2003;289:3095-105.
10. Schweiger U, Deuschle M, Korner A, et al. Low lumbar bone mineral
density in patients with major depression. Am J Psychiatry. 1994;151:1691-
1693.
11. Kristiansen C. Catching secondary causes of osteoporosis. Endocrine
News. 2006:1.
sweat collected for several hours as a valid and practical
alternative in ambulatory settings. RIC and other ultra-
sensitive methods should be used.
Depression, leptin, adiponectin, and risk of diabetes
and obesity
Future studies should establish whether a causal link
exists between MDD and decreased daily production of
adiponectin. These studies should be large enough and
of sufficient duration to detect clinical events such as
T2DM or CVD. The effects of antidepressants on
adiponectin should be investigated, as should the mech-
anisms that lead to decreased adiponectin and increased
leptin secretion, respectively. 
Glucocorticoid receptor gene polymorphism
Future research should focus on establishing the role of
the Bcl1 GG genotype of GR gene in metabolic syn-
drome within larger studies of women with active
MDD.
Depression, chronic pain, and quality of life
Women with depression should be clinically screened for
pain and patients complaining of pain, especially if not
clearly attributable to an identifiable organic process
should be evaluated for depression. Quality of life is sub-
stantially affected even in mild depression. Future
research should establish the role of MDD in the natural
history of pain, attempt to characterize the biological
mechanisms predisposing to pain, and determine
whether men with depression also have increased preva-
lence of pain symptoms.
Conclusions
We propose that the sample of women with MDD stud-
ied in the POWER Study is representative of a distinct
emerging clinical phenotype characterized by osteope-
nia, an increased risk for insulin resistance and cardio-
vascular disease, a chronic state of subclinical inflam-
mation, increased diathesis to coagulopathy states, major
endocrine, immune, and neuropeptide alterations, and
increased propensity to chronic pain (Figure 7). 
The collective body of evidence generated in the POWER
Study and summarized here has established the novel con-
cept that the medical consequences of depression previ-
ously thought to be limited to severely depressed, unmed-
icated subjects are definitely present also in the milder
clinical forms. Of note, these women were mildly
depressed or in either spontaneous or medication-induced
clinical remission, and highly functional in these conditions.
As these clinical forms represent epidemiologically the
majority of subjects with depression, and bearing in mind
the high lifetime prevalence of major depression, a chronic
and recurrent condition, this phenotype has major clinical
and public health implications.
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El trastorno depresivo mayor es un factor de
riesgo para una masa ósea disminuida, 
obesidad central y otras condiciones médicas
El trastorno depresivo mayor (TDM) es una de las
enfermedades psiquiátricas más comunes en la
población adulta. A menudo está asociada con un
aumento del riesgo de enfermedad cardiovascular.
La osteoporosis también constituye una importante
amenaza para la salud pública. Hay múltiples estu-
dios que han dado cuenta de una asociación entre
depresión y baja en la densidad mineral ósea, pero
aun se discute una relación causal entre estas dos
condiciones. En este artículo se resumen los hallaz-
gos más importantes del estudio POWER (preme-
nopausia, osteoporosis de la mujer, alendronato,
depresión), un extenso estudio sobre el recambio
óseo en la mujer premenopáusica con depresión
mayor. Además se revisan las alteraciones endocri-
nas e inmunes secundarias a la depresión que pue-
den afectar la masa ósea y el posible papel de un
pobre estilo de vida en la etiología de la osteopo-
rosis en sujetos con depresión, como también el
potencial efecto de los antidepresivos en la pérdida
ósea. Se postula que la depresión induce pérdida
ósea y fracturas osteoporóticas, lo que ocurriría pri-
mariamente a través de mecanismos inmunes y
endocrinos específicos; en cambio los pobres hábi-
tos de estilo de vida serían potenciales factores con-
tribuyentes. 
Le trouble dépressif majeur est un facteur
de risque de faible masse osseuse, d'obésité
centrale et d'autres pathologies
Le trouble dépressif majeur (TDM) est l’une des
maladies psychiatriques les plus courantes dans la
population adulte, souvent associée à un risque aug-
menté de maladie cardiovasculaire. L’ostéoporose
représente également un problème majeur de santé
publique. De nombreuses études ont montré une
association entre la dépression et une faible densité
minérale osseuse mais le lien causal entre les deux
affections fait l’objet de discussions. Cet article
résume les résultats les plus importants de l’étude
POWER (Premenopausal, Osteoporosis Women,
Alendronate, Depression), vaste étude prospective
sur le renouvellement osseux des femmes prémé-
nopausées atteintes de dépression majeure. Sont
aussi étudiés les modifications immunitaires et endo-
criniennes secondaires à la dépression pouvant
influer sur la masse osseuse, le rôle possible d’un
style de vie inadapté dans l’étiologie de l’ostéopo-
rose chez les personnes déprimées ainsi que l’effet
potentiel des antidépresseurs sur la perte osseuse. Il
est suggéré que la dépression induise une perte
osseuse et des fractures ostéoporotiques principale-
ment par le biais de mécanismes spécifiques immuns
et endocriniens, les mauvaises habitudes de vie y
contribuant éventuellement.
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